{"id":"NCT01418339","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-07-27","primaryCompletion":"2013-11-06","completion":"2013-11-06","firstPosted":"2011-08-17","resultsPosted":"2021-10-07","lastUpdate":"2021-10-07"},"enrollment":135,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Tourette's Disorder"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["ABILIFY"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Aripiprazole","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of the current study is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.","primaryOutcome":{"measure":"Change From Baseline in Yale Global Tic Severity Scale (YGTSS) - Total Tic Score (TTS)","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Aripiprazole","deltaMin":-12.34,"sd":0.88},{"arm":"Placebo","deltaMin":-7.72,"sd":1.23}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0028"}]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":19},"locations":{"siteCount":39,"countries":["United States","Canada","Hungary","Mexico","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":90},"commonTop":["Somnolence","Nausea","Headache","Vomiting","Fatigue"]}}